Neurology Archives | Page 295 of 322

Neurology

Higher-Dose Nusinersen Meets Primary End Point in Phase 2/3 DEVOTE Study for Spinal Muscular Atrophy

Based on the positive topline data, the company plans to submit for regulatory approval for…

September 5, 2024

Neurology

Vutrisiran Significantly Reduces Risk of Death and Cardiovascular Events in Phase 3 Study of ATTR Amyloidosis With Cardiomyopathy

Treatment with vutrisiran was associated with benefits across multiple well-established clinical measures of disease progression…

September 5, 2024

Neurology

Promise and Potential Challenges With Gene Therapy in Epilepsy: Imad Najm, MD

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided commentary…

September 5, 2024

Neurology

Multiple Sclerosis Disability Suppression Observed in New Fenebrutinib Phase 2 Data

MRI scans showed that 99% of fenebrutinib-treated patients were free of T1 gadolinium-enhancing lesions, indicating…

September 5, 2024

Neurology

Potential of Advancing Neurofibromatosis Care With Investigational Mirdametinib

Jim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, talked about how the prioritization…

September 4, 2024

Neurology

Denali’s DNL310 Eyes Accelerated FDA Approval With Encouraging Phase 1/2 Data in Hunter Syndrome

Post Content: Source: Neurology Read More

September 4, 2024

Neurology

FDA Clears Cortechs.ai’s NeuroQuant 5.0 Software for Quantification and Segmentation of ARIA-E and ARIA-H

NeuroQuant previously received clearance from the FDA as a medical device intended for automatic labeling,…

September 4, 2024

Neurology

FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07

AXS-07 has been supported by data from 2 major phase 3 trials in which treatment…

September 4, 2024

Neurology

Multisymptomatic Care in Parkinson’s Disease

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with…

September 4, 2024

Neurology

NeuroVoices: Crystal Proud, MD, on SMA Awareness Month, Advances in Research and TreatmentsNeuroVoices: Crystal Proud, MD, on SMA Awareness Month, Advances in Research and Treatments

The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters…

September 4, 2024

Neurology

Higher-Dose Nusinersen Meets Primary End Point in Phase 2/3 DEVOTE Study for Spinal Muscular Atrophy

Vutrisiran Significantly Reduces Risk of Death and Cardiovascular Events in Phase 3 Study of ATTR Amyloidosis With Cardiomyopathy

Promise and Potential Challenges With Gene Therapy in Epilepsy: Imad Najm, MD

Multiple Sclerosis Disability Suppression Observed in New Fenebrutinib Phase 2 Data

Potential of Advancing Neurofibromatosis Care With Investigational Mirdametinib

Denali’s DNL310 Eyes Accelerated FDA Approval With Encouraging Phase 1/2 Data in Hunter Syndrome

FDA Clears Cortechs.ai’s NeuroQuant 5.0 Software for Quantification and Segmentation of ARIA-E and ARIA-H

FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07

Multisymptomatic Care in Parkinson’s Disease

NeuroVoices: Crystal Proud, MD, on SMA Awareness Month, Advances in Research and TreatmentsNeuroVoices: Crystal Proud, MD, on SMA Awareness Month, Advances in Research and Treatments

Recent Posts

Trending Posts

New in Neurology

Categories

Neurology

Recent Posts

Trending Posts

Tags

New in Neurology

Categories